Osimertinib the gold standard for EGFR mutated T790M-positive advanced NSCLC

Lung cancer is a problem in South Africa with high morbidity and mortality rates, which are exacerbated by inequalities in…

Read More
CPD POINTS: 1

Emerging prognostic role of CgA in castration resistant PCa

Prostate cancer (PCa) is the most prevalent form of cancer in men worldwide. According to 2018 figures, close to four…

38 PCa treatment recommendations from the AUA

It is concerning that the number of men diagnosed with late stage cancer is increasing globally, notes the Cancer Association…

An oncologist’s view on nutrition in the cancer patient

A 2016 survey conducted among cancer patients found that about 73% of respondents experienced feeding problems during their illness and…

The tech, training and theory paradox

The pace of medical innovation and specifically technology is seemingly outstripping our ability to research the efficacy of each new…

Novel life-saving radiotherapy technology: How it can be made available in the developing world

Some examples of the new technologies are ultra-high dose rate (FLASH)-radiotherapy and the magnetic resonance imaging (MRI) linear accelerator, in…

What are the real-world outcomes of osimertinib for NSCLC patients?

Osimertinib is used to treat a type of non-small-cell lung cancer with a mutation in the EGFR gene.

No two breast cancers are the same

Breast cancer (BC) is the most common cancer diagnosis in women. In South Africa, BC accounted for 20.8% of all…

Breast cancer: Key findings from ASCO

Each year, the American Society of Clinical Oncology (ASCO), a professional organisation representing healthcare providers of all oncology sub-specialties, holds…

Biomarkers as tools in oncology

We chat to Prof Bernardo Rapoport, medical oncologist at the Medical Oncology Centre of Rosebank (Johannesburg), and extraordinary professor in…

Cancer care: When time is of the essence

For anyone who has been diagnosed with cancer, time is of the essence. In an ideal world, treatment plans should…

Patient-centric care benefits all

Against the backdrop of rising healthcare costs, value-based care (VBC) is the sustainable alternative to the current fee-for-service model, according…

Hybrid imaging: The future looks bright(er) for oncology patients

Imaging has become an indispensable tool in cancer research, clinical trials and medical practice. Over the past few decades, there…

How to prevent CAT

Cancer-associated thromboembolism (CAT) is the second most common cause of mortality in cancer patients (>40%). CAT also complicates the course…

Advanced and metastatic breast cancer: Is metronomic chemotherapy the answer?

In the 1940s the average five-year survival rate for all breast cancer (BC) patients was 53%. As a result of…

NSCLC: Latest treatment approaches

Globally, lung cancer occurred in about 2.1 million patients in 2018, with an estimated mortality of 1.8 million. This makes…

When men get cancer

Although all men are at risk of complications due to prostate enlargement, those who have a family history of prostate…

5 fertility preservation options for cancer patients

Over the past few decades, there has been a sharp increase in cancer survivors due to advancements in cancer therapeutics…

New advances in head and neck squamous cell carcinoma

Lose teeth, oral abscesses and inexplicable ear ache might be signs and of head and neck squamous cell carcinoma (HNSCC),…

Latest breast cancer trends

Breast cancer treatment has evolved over the last 50 years, from a disease treated mainly by surgeons to now being…

« » page 1 / 2